There is a strong interest in strategies to reduce the risks of osteoporosi
s and the related health care costs. The age of the population in civilized
countries is ever increasing. One of the concerns is to maintain a high qu
ality of life after retirement. Another concern is the continuous and explo
sive growth of public health care costs. This has lead to governmental meas
ures to let people pay relatively high own risks and self-contributions for
medical treatment. One of the results of these developments is a growing t
rend towards self-medication. Because drugs cannot be obtained without pres
cription, consumers seek for natural products to fit their needs and expect
ations. The food industry is aware of these developments and targets this e
ver growing market segment with an intensified search for food substances,
which may have a positive effect on health, disease prevention or disease m
anagement. Once established, the benefits are usually communicated as claim
s related to either the product or the consumer benefit. One of the basic q
uestions consumers are dealing with is whether the claims made are true and
not just misleading selling arguments. Recent developments in internationa
l food legislation point to a need to avoid the launch of products with uns
ubstantiated claims. Thus, functional or health claims related to specific
food ingredients or functional foods may only be approved by legal food aut
horities, if there is an international consensus on the supporting scientif
ic evidence. This article reviews current opinions on osteoporosis and high
lights a number of epidemiological, physiological and nutritional aspects.
(C) 2000 Elsevier Science Ltd. All rights reserved.